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Background
The history of gram-negative bacteria, lipopolysaccharides
(LPS, also called endotoxins), tumor necrosis factor (TNF), and
NF-κB is very closely intertwined and is linked to inflammation.
Fever, an inflammatory response, whether induced by viral
infection, bacterial infection, or another environmental stimulus,
invariably leads to loss of appetite and temporary infertility.
More than a century ago, the German physician Brunes showed
that gram-negative bacterial infection can produce tumor
regression. Bacterial extracts have been used until recently,
under the name “Coley’s toxins,” for cancer treatment
(Aggarwal, 2003). The antitumor principle in Coley’s toxins was
identified as LPS, a constituent of the bacterial cell wall that
interacts with the cellular receptor TLR4, leading to TNF produc-
tion from host macrophages (Aggarwal, 2003). TNF turned out
to be the most potent activator of NF-κB.
NF-κB was discovered by Baltimore and coworkers in 1986
as a factor in the nucleus of B cells that binds to the enhancer of
the kappa light chain of immunoglobulin (Sen and Baltimore,
1986). It has since been shown to be expressed ubiquitously in
the cytoplasm of all cell types, from Drosophila to man. It
translocates to the nucleus only when activated, where it 
regulates the expression of over 200 immune, growth, and
inflammation genes.
The activation of NF-κB is a double-edged sword. While
needed for proper immune system function, inappropriate NF-
κB activation can mediate inflammation and tumorigenesis.
That duality is especially striking in relation to cancer, a proin-
flammatory disease (Balkwill and Mantovani, 2001). Most
inflammatory agents mediate their effects through the activation
of NF-κB (see Figure 1A), and the latter is suppressed by anti-
inflammatory agents. Similarly, most carcinogens and tumor
promoters activate NF-κB, whereas chemopreventive agents
suppress it, suggesting a strong linkage with cancer (for refer-
ences, see Bharti and Aggarwal, 2002). Paradoxically most
agents, including cytokines, chemotherapeutic agents, and
radiation, that induce apoptosis also activate NF-κB (Beg and
Baltimore, 1996), indicating that NF-κB is a part of the cells’
autodefense mechanism and thus may mediate desensitization,
chemoresistance, and radioresistance (Wang et al., 1999a).
How NF-κB activation mediates tumorigenesis will be
addressed in this minireview.
Inactive NF-κB is present in the cytoplasm of all cells; only
when it is activated and translocated to the nucleus is the usual
sequence of events generated. Currently, NF-κB is known to
consist of a family of Rel-domain-containing proteins; e.g., Rel
A (also called p65), Rel B, c-Rel, p50 (also called NF-κB1), and
p52 (also called NF-κB2). Phosphorylation-dependent cleavage
of p100 produces p52, whereas p105 is cleaved to form p50.
Similarly, a family of anchorin-domain containing proteins—
IκBα, IκBβ, IκBγ, IκBαε, bcl-3, p105, and p100—keep NF-κB in
its inactive state within the cytoplasm. In the cytoplasm, NF-κB
consists of a heterotrimer of p50, p65, and IκBα. The phosphor-
ylation, ubiquitination, and degradation of IκBα releases the
p50-p65 heterodimer, which then translocates to the nucleus
and binds its specific 10 base pair consensus site
GGGPuNNPyPyCC. IκBα is phosphorylated at serine residues
32 and 34 by IκBα kinase (IKK), which consists of IKKα, IKKβ,
and IKKγ (also called NEMO). Gene deletion studies have indi-
cated that IKKβ is needed for NF-κB activation by TNF and most
other agents.
NF-κB is constitutively active in most tumor cell lines,
whether derived from hematopoietic tumors or solid tumors. It is
rarely found to be constitutively active in normal cells except for
proliferating T cells, B cells, thymocytes, monocytes, and astro-
cytes. Constitutively active NF-κB has been identified not only in
human cell lines but also in tumor tissues derived from patients
with multiple myeloma (Feinman et al., 1999), acute myeloge-
nous leukemia (Griffin, 2001), acute lymphocyte leukemia
(Kordes et al., 2000), chronic myelogenous leukemia (Baron et
al., 2002), and prostate (Palayoor et al., 1999) and breast can-
cers (Nakshatri et al., 1997). Suppression of NF-κB in these
tumor samples inhibits proliferation, causes cell cycle arrest,
and leads to apoptosis (for references, see Bharti and
Aggarwal, 2002), indicating the crucial role of NF-κB in cell pro-
liferation and survival.What causes the constitutive activation of
NF-κB in tumor cells is incompletely understood. Mutation of
IκBα (Wood et al., 1998), enhanced proteosomal activity
(Miyamoto et al., 1994), or enhanced inflammatory cytokine
expression (O’Connell et al., 1995) have all been cited.
Several carcinogens, such as 7,12 dimethyl-benz(a)anthracene
(DMBA) and cigarette smoke, and tumor promoters, such as
phorbol ester, can induce NF-κB activation (Banerjee et al.,
2002; Anto et al., 2002). TNF, which can mediate carcinogene-
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sis through induction of proliferation, invasion, and metastasis
of tumor cells (Shishodia et al., 2003; Chen et al., 2002), is per-
haps the most potent activator of NF-κB.The constitutive activa-
tion of NF-κB in tumor cells has numerous consequences, as
described below.
NF-κB proteins are oncogenes 
Certain members of the NF-κB family are oncogenic. Among
the Rel/NF-κB family members, c-Rel consistently transforms
cells in culture, is itself activated by a retroviral promoter inser-
tion in an avian B cell lymphoma, and is frequently amplified in
Hodgkin’s lymphomas, diffuse large B cell lymphomas, and
some follicular and mediastinal B cell lymphomas (Gilmore et
al., 2004). The avian Rev-T retrovirus encodes the v-Rel onco-
protein. v-Rel induces rapidly fatal lymphoma/leukemia in young
birds, and v-Rel can transform and immortalize a variety of
avian cell types in vitro. v-Rel is frankly oncogenic in animal
model systems. The potent oncogenicity of v-Rel is the conse-
quence of a number of mutations that have altered its activity
and regulation (Gilmore, 1999).
NF-κB activation can induce cellular transformation
Several oncogenes mediate their effects by activating NF-κB.
Among them is oncogenic Ras, which is constitutively active in
several tumor types (Mayo et al., 2001; Balmain and Pragnell,
1983), including prostate (Kim et al., 2002) and colon cancer.
Similarly, c-myc, which can mediate tumorigenesis (Kim et al.,
2000), is regulated by NF-κB. Pim-2, which is a transcriptionally
regulated oncogenic kinase, promotes cell survival through acti-
vation of NF-κB (Fox et al., 2003). Various viral proteins that
mediate tumorigenesis also signal through NF-κB activation.
These include Kaposi’s sarcoma-associated herpes virus
(KSHV), EBV latent membrane protein (LMP)-1, and human T
lymphocytic leukemia virus (HTLV)-1.
NF-κB activation mediates cellular proliferation
Numerous NF-κB-regulated cytokines are growth factors for
tumor cells. IL-1β is a growth factor for AML, TNF is a growth
factor for Hodgkin’s lymphoma, cutaneous T cell lymphoma,
and gliomas (Pahl, 1999); and IL-6 is a growth factor for multi-
ple myeloma (Kawano et al., 1988), among others. Both IL-1
and TNF mediate their proliferative effects through activation
of NF-κB (Osborn et al., 1989). EGF, a growth factor for many
different solid tumors, activates NF-κB (Biswas et al., 2000).
HER2, a growth factor receptor, is overexpressed in breast,
prostate, and other cancers; it too mediates its effects in part
through NF-κB activation (Bhat-Nakshatri et al., 2002; Myers
et al., 1996). Thus, both cytokines and cytokine receptors
either are regulated by NF-κB or mediate proliferation through
activation of NF-κB. Certain cell cycle proteins, such as cyclin
D1, needed for entry of cells from G1 to S phase, are also reg-
ulated by NF-κB.
NF-κB activation can mediate cellular invasion and angio-
genesis
Tumor invasion is regulated by numerous NF-κB-regulated
gene products, including matrix metalloproteinases (MMP),
urokinase type of plasminogen activator (uPA), interleukin-8
(IL-8), and other chemokines (see Figure 1B) (Farina et al.,
1999; Bond et al., 1998; Novak et al., 1991). It has been
reported that MMP-9 expression is regulated transcriptionally
through NF-κB elements within the MMP-9 gene (Farina et al.,
1999). Bond et al., using an adenovirus that overexpresses
the inhibitory subunit IκBα, found that NF-κB activation was an
absolute requirement in upregulation of MMP-9. uPA, another
critical protease involved in tumor invasion and metastasis, is
transcriptionally activated by PMA, IL-1, and TNFα. Activation
requires the induction of NF-κB activity and the decay of IκBα
(Novak et al., 1991). Wang et al. reported that uPA was over-
expressed in pancreatic tumor cells through constitutive RelA
activity (Wang et al., 1999b). The uPA promoter contains an
NF-κB binding site that directly mediates the induction of uPA
expression by RelA.
Among the growth factors that regulate angiogenesis are
the chemokines (e.g., MCP-1, IL-8), and growth factors (e.g.,
TNF, VEGF) produced by macrophages, neutrophils, and
other inflammatory cells (Loch et al., 2001). The production of
these angiogenic factors is regulated by NF-κB activation
(Chilov et al., 1997). NF-κB mediates the upregulation of IL-8
and VEGF expression in bombesin-stimulated PC-3 cells
(Levine et al., 2003). NF-κB expression has been implicated in
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Figure 1. Inducers of NF-κB activation and tumorigenic genes regulated by
NF-κB
A: Activation of NF-κB by inflammatory agents, carcinogens, tumor pro-
moters, viral proteins, stress, chemotherapeutic agents, and γ radiation.
B: Expression of numerous genes involved in cell survival, proliferation,
angiogenesis, inflammation, invasion, and metastasis is regulated by
activation of NF-κB.
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VEGF expression and the regulation of microvessel density in
human colorectal cancer (Yu et al., 2003). These studies fur-
ther underscore the role of NF-κB activation in mediating
angiogenesis.
NF-κB activation can mediate metastasis
Metastasis requires the migration of cancerous cells into and
out of the vessel walls that transport them to other parts of the
body.The ability to penetrate vessel walls is mediated by specif-
ic molecules expressed on the endothelial cells of the blood
vessels in response to a number of signals from inflammatory
cells, tumor cells, etc. Metastasis itself is mediated through the
expression of various adhesion molecules, including ICAM-1,
VCAM-1, and ELAM-1 (van de Stolpe et al., 1994), which are in
turn regulated by NF-κB (Figure 1B). The inducible nitric oxide
synthase (iNOS) has also been closely linked with metastatic
ability of the tumor (Thomsen and Miles, 1998), and it too is
regulated by NF-κB.
Helbig et al. have demonstrated that NF-κB regulates the
motility of breast cancer cells by directly upregulating the
expression of the chemokine receptor CXCR4 (Helbig et al.,
2003). Fujioka et al. showed that inhibiting constitutive NF-κB
activity by expressing mutant IκBα (IκBαM) suppressed liver
metastasis (Fujioka et al., 2003).These results all implicate NF-
κB in the migration and organ-specific homing of metastatic
breast cancer cells.
NF-κB links inflammation and cancer
Numerous lines of evidence exist to suggest that inflammation
mediates tumorigenesis (Vakkila and Lotze, 2004; Taketomi et
al., 1997). Clinically, Taketomi et al. demonstrated that an acti-
vated inflammation in a nontumorous portion of the liver was a
significant risk factor for recurrence in patients with small hepa-
tocellular carcinoma (Taketomi et al., 1997).The inflammation is
mediated through adhesion molecules, such as ICAM-1. In ani-
mal studies, Pidgeon et al. noted that surgical removal of a pri-
mary tumor is often followed by rapid growth of previously
dormant metastases (Pidgeon et al., 1999). They hypothesized
that LPS was responsible for this effect. As proof, BALB/c mice
that received a tail vein injection of 4T1 mouse mammary carci-
noma cells were subjected to surgical trauma or an LPS injec-
tion (intraperitoneal).These animals showed an increase in lung
metastasis five days later compared to anesthetized controls.
Tumor cell proliferation increased and apoptosis decreased
within lung metastases. Circulating levels of the angiogenic
cytokine VEGF were also elevated in these groups and correlat-
ed with increased plasma levels of LPS. Endotoxin treatment
directly upregulated VEGF production in vitro. These data indi-
cated that endotoxin introduced during surgery enhanced the
growth of metastases.
Harmey and colleagues also showed that LPS increased the
growth of experimental metastases in a murine tumor model
(Harmey et al., 2002). BALB/c mice bearing 4T1 lung metas-
tases given an i.p. injection of LPS had increased lung weight
and a higher incidence of pleural lesions. LPS injection
increased angiogenesis both in vivo and in vitro, and vascular
permeability in lung tissue was increased after LPS injection.
LPS increased inducible iNOS and MMP-2 expression in lung
tumor nodules. 4T1 cells transfected with green fluorescent pro-
tein (4T1-GFP) injected via the lateral tail vein appeared in lung
tissue on treatment with LPS, but not if the competitive NOS
inhibitor N(G) methyl-L-arginine was also given. They concluded
that LPS-induced growth and metastasis of 4T1 experimental
lung metastases are associated with increased angiogenesis,
vascular permeability, and tumor cell invasion/migration with
iNOS expression.
Genetic evidence that inflammation can mediate tumorige-
nesis was reported recently by Michael Karin’s group (Greten
et al., 2004; Luo et al., 2004), in which they manipulated the
levels of NF-κB in the tumors and its microenvironment. The
first report by Greten et al. examined IKKβ- mediated inflam-
mation and tumorigenesis in a mouse model of colitis-associat-
ed cancer (CAC). Tissue-specific deletion of IKKβ in
enterocytes and myeloid cells reduced the incidence and
development of CAC, but by different mechanisms. Deletion of
IKKβ in enterocytes greatly decreased colitis-associated tumor
incidence without affecting tumor size. Enterocyte-specific
deletion of IKKβ did not prevent dextran sulfate sodium salt
(DSS, an inflammatory agent)-induced inflammation, but
enhanced p53-independent apoptosis during early tumor pro-
motion. Exposure to azoxymethane (AOM, a procarcinogen)
and DSS led to IKK activation in control epithelial cells but not
in IKK knockout cells. p53, Mdm2, p21, and JNK were unal-
tered; expression of bcl-2 family members accounted for the
difference in apoptosis. This suggested that the expression of
IKKβ in enterocytes is important during early stages of tumor
initiation and/or promotion.
Karin’s group found that deletion of IKKβ in myeloid cells
decreased tumor growth without affecting apoptosis (Greten et
al., 2004). It also reduced the expression of IL-1α, IL-1β, IL-6,
KC, MIP2, TNF, COX2, and ICAM-1 in macrophages. Tumor
incidence was reduced by half. Although tumor morphology was
similar, the percentage of smaller tumors was higher. Apoptotic
and proliferation indices did not change. While enterocyte-spe-
cific deletion of IKK increased COX2 and MMP-9, myeloid-spe-
cific deletion of IKKβ decreased their expression. Thus, IKKβ
promoted tumor growth in myeloid cells through production of
tumor-promoting paracrine factors, rather than inhibition of
tumor cell apoptosis. Thus, in myeloid cells, IKKβ is involved in
production of inflammatory mediators that promote tumor
growth. Which growth factors were involved was not reported.
Thus, IKKβ in enterocytes contributed to tumor initiation and
promotion by expressing antiapoptotic protein (such as bcl-2),
whereas IKKβ in myeloid cells contributed through expression
of tumor growth factors.
In the second report, featured in this issue of Cancer Cell,
Karin and coworkers showed that activation of NF-κB by endo-
toxin in cancer cells produces inflammation-induced tumor
growth through expression of TNF, whereas inhibition of NF-κB
mediates tumor regression through TRAIL (Luo et al., 2004).To
demonstrate this, they used an experimental murine cancer
metastasis model in which an adenocarcinoma cell line gener-
ates lung metastasis. Its growth is stimulated by injection of
LPS. They found that LPS induced metastatic growth in this
model through TNF production by host hematopoietic cells and
NF-κB activation in tumor cells. Suppression of NF-κB in both
colon and mammary carcinoma cells converted the LPS-
induced growth response to LPS-induced tumor regression.
M I N I R E V I E W
206 CANCER CELL : SEPTEMBER 2004
The tumor regression response was TNF-independent but
TRAIL-dependent. LPS induced TRAIL receptor in NF-κB defi-
cient cells.
Luo et al. transfected a CT26 colon cancer cell line, which
metastasizes to lung, with an IκBα “super-repressor.” LPS
increased the weight of the lungs and number of tumor nodules
in BALB/c mice injected with CT26, but the IκBα super-repres-
sor significantly decreased lung weight and number of nodules.
They concluded that NF-κB activation is required for LPS-
induced tumor growth. LPS enhanced the proliferation of the
tumor, and NF-κB suppression led to apoptosis. LPS also short-
ened the life span of the animals injected with control cells line,
but not of those injected with the super-repressor transfected
line. LPS induced Bcl-xL, cIAP-1, cIAP2, MMP-9, and PCNA in
tumors derived from animals injected with control cell line, but
not in tumors from IκBα super-repressor cells.
Further investigation revealed that TNF mediates LPS-
induced tumor growth and NF-κB activation. LPS activated NF-
κB in the host cell (most likely macrophages) and induced
circulating TNF within 2 hr. No LPS-induced NF-κB activation
was noted in Tlr4lps-d mutant mice (LPS receptor). To examine
the role of TNF production/TNF signaling in tumor growth, bone
marrow from WT, type 1 TNF receptor-deficient (Tnfr1−/−) or
TNF-deficient (Tnf−/−) mice was transplanted into lethally irradi-
ated BALB/c mice to generate chimeric mice, which were then
inoculated with CT26 tumor cells. The lung tumor burden in
chimeric mice reconstituted with either WT or Tnfr1−/− bone mar-
row was significantly higher after LPS challenge. However, LPS
did not increase tumor burden in lungs from mice reconstituted
with Tnfα−/− bone marrow. This correlated with NF-κB activation.
These results suggest that TNF production by host hematopoi-
etic cells is required for activation of NF-κB in cancer cells and
stimulation of tumor growth.
How does suppression of NF-κB mediate tumor regres-
sion? The authors found that LPS-induced regression of NF-κB-
deficient tumors is mediated through production of TRAIL. A
role for TNF in LPS-induced tumor regression was ruled out, as
no difference in tumor burden was noted when CT/IκBα (AA)-
cells were inoculated in WT or Tnf−/− mice. Because tumor-bear-
ing lungs, not the tumors, from mice inoculated with either CT or
CT/IκBα (AA)-cells had elevated expression of Fas and TRAIL
after LPS administration, the authors proposed that TRAIL
mediates LPS-induced regression. Because Fas is not
expressed by CT26 cells, a role for FasL was ruled out. It is
intriguing to note that LPS did not induce TRAIL in the tumor,
but did induce in tumor-bearing lungs, suggesting that the
source of TRAIL was the lungs of the mice. Also, the LPS-
induced expression of TRAIL was, if anything, slightly higher in
mice bearing CT/vector than those with CT/IκBα (AA) tumors.
The lack of difference in LPS-induced TRAIL expression
between CT/vector and CT/IκBα (AA) suggests that NF-κB
does not have a role in TRAIL expression. Anti-TRAIL antibod-
ies reversed the LPS-induced tumor regression in mice bearing
CT/IκBα (AA) tumors. What effect anti-TRAIL antibody has on
LPS-induced tumor growth in mice bearing CT 26 tumor was
not examined. The question is important, because while TRAIL
inhibits the growth of some cell types, it promotes proliferation
of other cell types (Secchiero et al., 2003).
Luo et al. further showed that LPS induced DR5 expression
(TRAIL receptor II) in tumors from mice bearing CT/IκBα (AA)
but not CT/vector, suggesting NF-κB does not have a role in
DR5 expression either (Luo et al., 2004). This contradicts pub-
lished reports that NF-κB activation is needed for DR5 expres-
sion (Ravi et al., 2001). Luo’s group concluded that
JNK-mediated p53 phosphorylation was responsible for DR5
expression. Overall, these results provide evidence, at the
genetic level, that inflammatory response generated through
the activation of NF-κB plays a critical role in tumorigenesis.
NF-κB activation prevents tumorigenesis
It is possible that NF-κB has different roles in different cell
types. Seitz et al. found that in normal epidermis, NF-κB pro-
teins existed in the cytoplasm of basal cells and then localized
to the nuclei of suprabasal cells, suggesting that NF-κB medi-
ates the switch from proliferation to growth arrest and differen-
tiation (Seitz et al., 1998). Functional blockade of NF-κB
created by expressing dominant-negative NF-κB inhibitory
proteins in transgenic murine and human epidermis produced
hyperplastic epithelium in vivo. Consistent with this, applica-
tion of a pharmacologic inhibitor of NF-κB to intact skin
induced epidermal hyperplasia. In contrast, overexpression of
active p50 and p65 NF-κB subunits in transgenic epithelium
produced hypoplasia and growth inhibition. These data sug-
gest that spatially restricted NF-κB activation occurs in strati-
fied epithelium and indicate that NF-κB activation in this
tissue, in contrast to its role in other settings, is important for
cellular growth inhibition.
van Hogerlinden et al. showed that selective inhibition of
NF-κB signaling in murine skin, by targeted overexpression of
a super-repressor form of IκBα, results in an increased basal
frequency of apoptotic cells and the spontaneous development
of squamous cell carcinomas (van Hogerlinden et al., 1999).
The presence of hyperplasia and hair follicle degeneration
demonstrated an important role for Rel/NF-κB signaling in nor-
mal epidermal development and homeostasis. Transgenic skin,
in addition, showed an enhanced sensitivity to UV-induced
apoptosis. These data suggest an involvement of the Rel/NF-
κB signaling pathway in apoptosis and cancer development of
the skin.
Dajee et al. showed that NF-κB blockade triggered inva-
sive human epidermal neoplasia (Dajee et al., 2003). The inhi-
bition of NF-κB enhanced apoptosis in certain tumors, and
blockade of NF-κB predisposed murine skin to squamous cell
carcinoma. They showed that in normal human epidermal
cells, NF-κB triggered cell-cycle arrest. Thus, these reports
suggest that suppression of NF-κB could be tumorigenic
under some conditions.
Conclusion
That inflammation plays a major role in tumorigenesis is
becoming evident. Most, if not all, of the inflammatory effects
are mediated through NF-κB activation. Its activation controls
the expression of genes that mediate transformation,
proliferation, invasion, angiogenesis, and metastasis on the
negative side of the ledger, and apoptosis, immunity, and
hematopoiesis on the positive side. While numerous pharma-
ceutical companies are developing inhibitors of NF-κB for the
treatment of cancer, these inhibitors should be tested with
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caution in view of the dual nature of NF-κB, in which either its
activation or inactivation may lead to tumorigenesis, depend-
ing upon circumstances. Cancer is a proinflammatory dis-
ease, as indicated by the fact that aspirin, an established
NF-κB blocker and an anti-inflammatory agent, has now
shown promise in the treatment of certain cancers. Blockers
of NF-κB that are nontoxic, such as plant polyphenols, should
be beneficial not only in prevention but also in the treatment
of cancer.
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